NEW YORK, Oct. 2 - Young, private genomic companies in the US anxious about a constricting venture capital market can breathe easy.

Despite sharp drops in the stock market, a receding overall venture capital tide, and the economic uncertainty brought on by the terrorist assault on the US three weeks ago, industry analysts believe that the private equity environment for early-stage genomic companies remains robust, has been outperforming the overall VC market, and shows signs of growth in the new year.

To read the full story....

Register for Free.

...and receive Daily News bulletins.

Already have a GenomeWeb or 360Dx account?
Login Now.

The Washington Post reports on a Federal Bureau of Investigation plan to place rapid DNA analyzers at booking stations around the country.

In an editorial, officials from scientific societies in the US and China call for the international community to develop criteria and standards for human germline editing.

The US National Institutes of Health is to review studies that have received private support for conflicts of interest, according to the New York Times.

In Science this week: the PsychENCODE Consortium reports on the molecular mechanisms of neuropsychiatric disorders, and more.